Albert Bourla is the CEO of Pfizer, a major player in the pharmaceutical industry, since January 2019. He joined Pfizer back in 1993 and has climbed the ranks, holding several key roles including Chief Operating Officer. His journey through various...

Albert Bourla is the CEO of Pfizer, a major player in the pharmaceutical industry, since January 2019. He joined Pfizer back in 1993 and has climbed the ranks, holding several key roles including Chief Operating Officer. His journey through various divisions has given him deep insights into the company's operations worldwide. His leadership became even more prominent during the COVID-19 pandemic, with Pfizer developing a key vaccine at record speed. In addition to being CEO, Bourla became Chairman of the Board in 2020, showing his strong influence over company direction. He’s also committed to healthcare globally, actively engaging with the Pfizer Foundation and serving on several health-related boards. In 2023, Bourla's total compensation was around $21.56 million, although he didn't receive a bonus due to underperformance against some financial goals. His previous years saw much higher bonuses, particularly in 2022, which reflects the fluctuations in the pharmaceutical market. His personal investment in the company is significant; last valued at over $29 million in February 2023, with a good chunk being in stock and stock rights. This indicates he believes in Pfizer's long-term success and is not just in it for the paycheck. He also holds a Doctor of Veterinary Medicine degree, adding an academic layer to his extensive experience in pharmaceuticals. Beyond Pfizer, he is known for contributing to healthcare through various boards that focus on improving access to innovative treatments.